Genotoxicity evaluation of cannabidiol

Area of Science:

• Pharmacology
• Toxicology
• Genetics

Background:

• Consumer interest in cannabidiol (CBD) for wellness is high, but safety data, particularly genotoxicity, are limited.
• Existing studies often lack quality due to impure test materials or suboptimal study designs, creating a regulatory data gap.

Purpose of the Study:

• To comprehensively assess the genotoxic potential of a pure CBD isolate.
• To address the identified data gap regarding CBD safety for regulatory bodies and consumers.

Main Methods:

• A battery of three standard genotoxicity assays were performed according to OECD guidelines.
• In vitro tests included a microbial reverse mutation assay (Ames test) and an in vitro micronucleus assay in human cells.
• An in vivo micronucleus assay was conducted in rats, with bioanalysis of CBD and its metabolite.

Main Results:

• CBD isolate tested negative for genotoxicity in the in vitro microbial reverse mutation assay up to 5000 μg/plate.
• CBD isolate tested negative in the in vitro micronucleus assay in human cells up to 10-11 μg/mL.
• CBD isolate tested negative in the in vivo micronucleus assay in rats up to 1000 mg/kg-bw/d, with confirmed dose-related plasma exposure.

Conclusions:

• The conducted genotoxicity assays indicate that pure CBD isolate is unlikely to pose a genotoxic hazard.
• These findings contribute crucial safety data to the public domain regarding CBD use.
• The study supports the safety profile of CBD for consumer wellness applications.